Investing
Genentech (DNA) Will Regret Turning Roche Down
Published:
Last Updated:
The board of Genentech (DNA) turned down an $86.50 offer by Roche to buy the part of the company that it does not already own.
Until about a month ago, the offer had been higher–$89.
The board is making a huge mistake and it is likely to cost shareholders a bundle. After the first offer was made last July, DNA shares moved above $90. They stayed there through the summer. As doubts emerged about the Roche offer, the stock moved back down to $85, which is where it trades today.
What the Genentech board is avoiding is the fact that its stock has not been consistently above $90 since 2005.
Genentech asked Roche for $112 a share. It is not dealing from a position of strength. There are not likely to be other buyers during an economic downturn.
When Genentech announced earnings for its last quarter and issued its 2009 forecast, both were below Wall St. expectations. If it walks way from the Roche deal, its shares will drop back to where they were when the whole matter started–$75.
Douglas A. McIntyre
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.